Acumen outlined late-2026 topline expectations for its fully enrolled ALTITUDE-AD Phase 2 IV study of sabirnetug (ACU193).
Program focus remains early Alzheimer’s disease, targeting toxic amyloid beta oligomers with a selective IgG2 monoclonal antibody.
Cash, cash equivalents, and marketable securities were about $110 million as of June 30, 2026; runway is projected into early 2027.
The Enhanced Brain Delivery program advanced with preclinical candidate data; lead BBB-penetrating oligomer antibody IND filing is targeted for mid-2027.
Phase 1 data cited a low ARIA-E incidence of about 10%, including zero cases in ApoE4 homozygotes in a small cohort.
ABOS•
